It's Not All About IO: Seven Drugs To Watch At ASCO

Biomedtracker's review of ASCO abstracts revealed several drugs to watch outside of the immuno-oncology space at the annual cancer conference in Chicago, including market-expanding data for Roche's Perjeta and J&J's Zytiga, and Phase III data for AstraZeneca's PARP inhibitor Lynparza in breast cancer.

The 2017 American Society of Clinical Oncology (ASCO) Annual Meeting is two weeks away, but the release of abstracts for data that will be presented during the conference provides a glimpse of which drugs may grab significant market share based on recent clinical trial results – and not all of them are immuno-oncology drugs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

01 May 2025

• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

Can European Biotech Survive And Thrive In Era Of Instability?

30 Apr 2025

• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.

GSK Chief Optimistic About BD Despite Volatile Environment